Journal of Clinical and Aesthetic Dermatology

MAY 2018

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: https://jcadonline.epubxp.com/i/979610

Contents of this Issue

Navigation

Page 35 of 55

36 JCAD JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY May 2018 • Volume 11 • Number 5 O R I G I N A L R E S E A R C H (Table 2). This single severe TEAE was adjudicated as unrelated to ixekizumab and resolved without changing treatment. There were no serious adverse events, deaths, or discontinuations during the trial. DISCUSSION Previous studies of the efficacy of ixekizumab in patients with moderate- to-severe plaque psoriasis established the efficacy and safety of ixekizumab over long-term treatment in patients with moderate-to-severe plaque psoriasis. 3,4 The current study was designed specifically to evaluate the early improvement in disease in response to ixekizumab and to determine the speed of onset of efficacy. In parallel to these quantitative assessments of efficacy, this study also assessed the qualitative visual improvement in psoriasis symptoms in response to ixekizumab treatment by obtaining sequential photographs of participants over time. Although limited by a small patient population and lack of a placebo comparator, this study demonstrated that ixekizumab treatment resulted in a rapid and early onset of efficacy in as early as one week of treatment. In addition, the early clinical responses were maintained throughout the 48-week study, consistent with previously published results showing long-term maintenance of efficacy for patients receiving ixekizumab. 3,4 Sequential patient photographs also demonstrated a rapid improvement in plaque psoriasis. Visible improvement was evident within one week of treatment and continued to improve over time. At 48 weeks of treatment, photographs demonstrated the maintenance of visible improvement in psoriasis symptoms, consistent with a persistent clinical response. CONCLUSION Patients with moderate-to-severe plaque psoriasis exhibited a rapid clinical response and visible improvement in psoriasis in response to treatment with 80mg of ixekizumab every two or four weeks. Both clinical response and visible improvement in disease were evident within one week and persisted through 48 weeks of treatment. There were no unexpected safety concerns observed during the study. FIGURE 4. Visible clearance of psoriatic plaques over 48 weeks of treatment with IXE Q2W/Q4W—A 27-year-old woman with baseline PASI score of 19.2 and 12-percent BSA. Patient achieved PASI 75 at Week 4 and PASI 90 at Week 36, which was maintained through Week 48. BSA: body surface area; IXE: ixekizumab; PASI: Psoriasis Area and Severity Index; Q2W: every two weeks; Q2W/Q4W, 80mg IXE Q2W during the induction dosing period and Q4W during the maintenance dosing period; Q4W: every four weeks FIGURE 3. Visible clearance of psoriatic plaques over 48 weeks of treatment with IXE Q2W/Q4W—A 40-year-old man with a baseline PASI score of 13 and a 10% BSA achieved PASI 75 at Week 3, PASI 90 at Week 4, and PASI 100 at Week 8, which was maintained through Week 48. BSA: body surface area; IXE: ixekizumab; PASI: Psoriasis Area and Severity Index; Q2W: every 2 weeks; Q2W/Q4W, 80mg IXE Q2W during the induction dosing period and Q4W during the maintenance dosing period; Q4W: every 4 weeks

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - MAY 2018